This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bristol-Myers Squibb Company

Drug Names(s): Paclitaxel

Description: Taxol inhibits cell proliferation by stabilizing microtubules. Microtubules are cylindrical structures that form the basis of the cellular skeleton and are essential to the reproduction, growth, and spread of tumor cells. Normally, as a part of the mitotic process, microtubules are reorganized to form a spindle. Taxol binds tubulin, promoting polymerization and preventing de-polymerization of microtubules, resulting in cell death.

Deal Structure: DRI Capital
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Taxol for breast cancer, lung cancer and ovarian cancer. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.

Partners: DRI Capital Inc.

Taxol News

Pink Sheet Taxol FDA Reviewers

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug